BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
The FDA handed Rejoni a significant win on September 29, granting Premarket Approval (PMA P250051) for the Juveena Hydrogel System, the company’s flagship women’s-health product. It is indicated for adult women to reduce the incidence and severity of intrauterine adhesions following hysteroscopic adhesiolysis for symptomatic moderate-to-severe disease, according to the company’s announcement via Business Wire (reported by VentureBeat).
What happened
- The FDA granted Premarket Approval (PMA P250051) to the Juveena Hydrogel System on September 29, 2026.
- It is a hydrogel delivered through a proprietary transcervical catheter at the end of a hysteroscopic procedure; it forms in situ, conforms to the uterine cavity, and separates the uterine walls while tissue heals.
- Within roughly 14 to 21 days, the hydrogel softens, liquefies, and is naturally discharged through the cervix and vagina — no second removal procedure is needed.
- Approval was supported by a multicenter, randomized, subject- and evaluator-blinded pivotal study.
Why it matters
Intrauterine adhesions (Asherman’s syndrome) are a stubborn problem: they can cause menstrual disruption, infertility, recurrent pregnancy loss, and serious obstetric complications, and recurrence after surgical removal is common — women with severe disease often face repeated procedures. A barrier device that can be placed during the initial surgery and then disappears on its own fills a real clinical gap.
For investors, the approval validates Rejoni, a commercial-stage women’s-health company out of Bedford, Massachusetts, and gives it a marketed product to build a commercial engine around. The PMA route — the FDA’s most stringent device pathway — also signals the evidence bar the data cleared, which matters for any future label expansions.
What to watch
- Commercial rollout timing and pricing — the company has not yet disclosed launch details or a price point.
- Physician adoption and real-world recurrence data, which will determine whether Juveena becomes standard practice after adhesiolysis.
- Any follow-on indications or pipeline products Rejoni advances on the back of this approval.
Related reading: our recent FDA-approval coverage — Roche Fenebrutinib Wins FDA Priority Review for Relapsing and Progressive MS and FDA to Decide on Bristol Myers’ Camzyos for Adolescents on Sept. 30.
Do device approvals like this get enough investor attention compared with drug approvals? Share your view in the comments.
Source: VentureBeat (Business Wire release)
Auto-posted by the Bull Lounge news desk. Not financial advice.
Log in to vote
